Urothelial neoplasms are the most common urinary tract cancers and can be located in the lower (bladder and urethra) or upper (pelvocalyceal cavities and ureter) urinary tract. Bladder tumors make up 90%--95% of all urothelial malignancies \[[@b1-jptm-49-5-389]\], while upper urinary tract urothelial carcinomas (UUTUCs) are uncommon and make up only 5% \[[@b2-jptm-49-5-389]-[@b4-jptm-49-5-389]\]. The natural history of bladder tumors and UUTUCs differ; 60% of UUTUCs, but only 15% of bladder tumors, are found to be invasive at the time of diagnosis \[[@b5-jptm-49-5-389]-[@b7-jptm-49-5-389]\]. Tumor stage, histological grade, lymph node involvement, and type of surgical procedure used have been shown to be significant prognostic factors for urothelial carcinomas \[[@b8-jptm-49-5-389]-[@b10-jptm-49-5-389]\]. Several classical clinicopathological, morphometric, cytometric, immunohistochemical, and molecular markers have also been shown to have prognostic significance, but the search for markers that affect patient outcome continues.

Parafibromin is a protein encoded by the hyperparathyroidism 2 (*HRPT2*) tumor suppressor gene. Mutations of this protein lead to autosomal dominant hyperparathyroidism-jaw tumor syndrome with parathyroid adenoma or carcinoma, mandibular or maxillary fibro-osseous tumors, and renal neoplastic and non-neoplastic abnormalities such as Wilms' tumor, hamartoma, or cystic renal disease \[[@b11-jptm-49-5-389]-[@b13-jptm-49-5-389]\]. The *HRPT2* gene, located in human chromosome 1q31.2, consists of 17 exons and spans 18.5 kb in the genome. The 2.7-kb transcript that it encodes is translated into a 531-amino acid parafibromin protein with a molecular weight of 60 kD \[[@b14-jptm-49-5-389],[@b15-jptm-49-5-389]\]. This gene might function as a tumor suppressor gene as *HRPT2*-inactivating mutations have been reported in various malignancies \[[@b16-jptm-49-5-389]-[@b21-jptm-49-5-389]\]. These findings suggest a potential role of parafibromin in the pathogenesis and progression of malignancy.

The role of the newly discovered tumor suppressor gene parafibromin in urothelial carcinoma has not been investigated. We evaluated the immunohistochemistry of parafibromin expression in urothelial carcinoma and paired benign urothelium from patients undergoing transurethral resection, radical cystectomy (RC), and nephroureterectomy. The aim was to investigate the expression of parafibromin in urothelial carcinoma and to determine its role in tumor behavior and prognosis in urothelial carcinoma (UC) patients.

MATERIALS AND METHODS
=====================

Patient and tissue selection
----------------------------

The study cohort consisted of 49 cases diagnosed as urothelial carcinoma at a single center between January 2006 and December 2013. A total of 49 surgical specimens from 21 transurethral resections, 11 radical cystectomies, and 17 nephroureter-ectomies were retrospectively reviewed. Survival periods were calculated based on patient demographics. All patients provided consent for use of their tumor tissue for clinical research, and the Sifa University Ethics Committee approved the research protocol. We assessed patient medical charts for clinical features such as progression, recurrence, and presence and number of near and distant metastases.

Histopathological evaluation
----------------------------

All surgical specimens were processed according to standard pathology procedures and were histologically confirmed to be urothelial carcinoma. Tumor grading was performed according to the 2004 World Health Organization--International Society of Urological Pathology Consensus Classification \[[@b22-jptm-49-5-389]\]. Tumor architecture was defined as papillary or non-papillary based on the predominant feature of the index lesion.

Immunohistochemical evaluation of parafibromin
----------------------------------------------

Formalin-fixed and paraffin-embedded tissue specimens were prepared for immunohistochemical (IHC) staining for all patients. A demonstrative block containing benign urothelium tissue adjacent to the tumor was selected for IHC evaluation. Sections 4--5-μm-thick were prepared from the paraffin-embedded tissues and were placed on electrostatic-charged slides (X-tra, Surgipath Medical Industries, Richmond, IL, USA). Sections were deparaffinized and dehydrated through a graded ethanol series using routine protocols. The IHC study was performed using parafibromin (1:100, HRPT2, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Slides from parathyroid adenoma cases were used as positive controls. The IHC staining process, including deparaffinization and antigen retrieval, was performed on a Dako LV-1 automated immunostaining system (Dako, Glostrup, Denmark). Scoring was performed separately by two pathologists who were blinded to patient characteristics. Nuclear staining was accepted as positive for parafibromin. The staining pattern was classified as diffusely and strongly positive when there was nuclear staining in all or nearly all (i.e., \>95%) of the tumor cells regardless of staining intensity, negative when there was almost no staining (\< 1%) of tumor nuclei, and partially positive in all other cases \[[@b17-jptm-49-5-389]\]. A negative result was reported only if there was an internal positive control. There was no difference between the grades of the two pathologists.

Statistical data analysis
-------------------------

The SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA) software program was used for statistical analyses. In addition to descriptive statistical methods, the chi square test and Fisher exact test were used for the comparison of categorical variables. Binary numerical data were compared with the Mann-Whitney U test. Survival data were obtained with Kaplan-Meier, log rank, and Cox regression analyses. A p-value of \<.05 was accepted as statistically significant.

RESULTS
=======

Clinical and pathological parameters
------------------------------------

The mean age was 69.55±8.2 years (range, 54 to 88 years), and men made up 85.7% (n = 42) of the group. [Table 1](#t1-jptm-49-5-389){ref-type="table"} presents the clinicopathological features of the subjects. The follow-up range was 3 to 96 months. There were three deaths due to tumor during follow-up. Tumor progression (including development of invasive features, deep invasion, lymph node metastasis, and distant organ metastasis) was seen in 19 cases. Mean survival duration was 37.88±29.6 months. Mean disease-free progression in the recurrence-free cases was 26.98±26.2 months. There was a statistically significant relationship between tumor subtype and tumor grade and muscularis propria invasion (p=.01 and p = .001, respectively) ([Table 2](#t2-jptm-49-5-389){ref-type="table"}). All low-grade non-invasive tumors were of the papillary subtype, while high-grade tumors were mainly of the non-papillary subtype. Invasion was found in five of six high-grade UCs with squamous differentiation. There was no statistically significant relationship between tumor subtype and tumor localization, gender, age, presence or number of recurrences, presence of progression, survival, or disease-free survival ([Table 2](#t2-jptm-49-5-389){ref-type="table"}).

The relationship between parafibromin expression and urothelial carcinoma
-------------------------------------------------------------------------

Parafibromin expression was negative in 13 cases (26.5%), partially positive in 19 cases (38.8%), and positive in 17 cases (34.7%) ([Table 3](#t3-jptm-49-5-389){ref-type="table"}, [Figs. 1](#f1-jptm-49-5-389){ref-type="fig"}[](#f2-jptm-49-5-389){ref-type="fig"}--[3](#f3-jptm-49-5-389){ref-type="fig"}). There was a statistically significant relationship between parafibromin expression and muscularis propria invasion and tumor location (upper/lower urinary system). It was interesting that parafibromin was more negative in UCs with muscularis propria invasion than in tumors that did not invade muscle (p = .007). Parafibromin expression was higher in tumors of the lower urinary system than in upper urinary system tumors (p=.009). There was no statistically significant relationship between parafibromin expression and gender, age, tumor grade, presence and number of recurrences, presence of progression, survival, or disease-free survival ([Table 3](#t3-jptm-49-5-389){ref-type="table"}). Parafibromin positivity in the normal urothelial epithelium adjacent to the tumor was seen in nine cases ([Fig. 4](#f4-jptm-49-5-389){ref-type="fig"}). The positivity rate in normal urothelial epithelium was 50% to 90%.

DISCUSSION
==========

Parafibromin is a tumor suppressor gene that has attracted interest for its potential prognostic value in some tumor types, especially parathyroid tumors. Its use as a potential indicator of tumor aggressiveness has been reported in other organs (e.g., colon, stomach, and breast) \[[@b18-jptm-49-5-389],[@b20-jptm-49-5-389],[@b21-jptm-49-5-389]\]. To the best of our knowledge, there has not been a study on parafibromin staining in UCs in the English literature. The main aim of this study was to contribute to establishing criteria that can predict the behavior of tumors in suspect cases. We also evaluated the presence of statistically significant relationships between parafibromin staining and other prognostic parameters. Parafibromin expression was weaker in UCs with muscularis propria invasion than in those without invasion of the muscle. Parafibromin staining was more common in lower urinary system UCs than in those of the upper urinary system. The parafibromin staining data in our study correlates with that of previous parafibromin staining studies of malignancies of other systems. Selvarajan *et al*. \[[@b18-jptm-49-5-389]\] observed an inverse correlation between tumor size and parafibromin expression in 163 breast carcinoma cases (p=.05). Zheng *et al*. \[[@b20-jptm-49-5-389]\] observed that lymph node metastasis and prognosis are related to parafibromin expression in colorectal carcinoma. Compared with the non-neoplastic colorectal mucosa, adenomas and carcinomas had decreased nuclear expression of parafibromin messenger RNA level. Zheng *et al*. \[[@b21-jptm-49-5-389]\] also reported that parafibromin expression gradually decreased in carcinoma areas compared to the normal gastric mucosa areas, and statistically significant relationships between parafibromin and lymphatic invasion, invasion depth, lymph node metastasis, and tumor stage were observed. The rate of muscularis propria invasion in bladder carcinomas is estimated to be 20%--30% at the time of diagnosis. Muscularis propria invasion results in progression in 20%--50% of cases, even if the tumor is diagnosed early \[[@b23-jptm-49-5-389],[@b24-jptm-49-5-389]\]. We found a statistically significant relationship between parafibromin expression and muscularis propria invasion, which suggests that this biomarker can function as an indicator of progression.

The rate of upper urinary system recurrence (UUSR) following RC is low (0.7% and 7.4%) but indicates a worse prognosis. The most important independent factors predicting UUSR following RC are number of metastatic lymph nodes and presence of local recurrence in the renal pelvis \[[@b25-jptm-49-5-389]\]. We did not find a statistically significant relationship between parafibromin expression and recurrence or progression in tumors that were removed by cystectomy, but parafibromin negativity was relatively prominent in recurring and progressive cases.

Urothelial carcinomas with squamous differentiation are known to have a poor prognosis. Their clinical course depends on the extension of the tumor to adjacent tissue and lymph nodes, requiring prompt radical surgery. Studies on the development mechanism and postoperative treatment of these tumors are ongoing \[[@b26-jptm-49-5-389]\]. We did not find a marked difference in the diffuseness or intensity of parafibromin staining in the six tumors of this group (three were strongly positive, one was positive, and two were negative). However, two patients died (one with a tumor in the ureter, and the other with a tumor in the renal pelvis), which is consistent with data from the literature.

Although our study focused on UC, we also took into account the transition areas with normal urothelial epithelium during sample selection. All nine cases of normal urothelial epithelium in the observed areas were positive for parafibromin. Porzionato *et al*. \[[@b27-jptm-49-5-389]\] have evaluated parafibromin staining in human and mouse tissues and reported that human bladder epithelium did not stain with parafibromin. However, the normal epithelium showed positive parafibromin staining in our cases. We are not sure of the cause of this discrepancy, but it could be related to differences in the parafibromin stain.

We found that the infiltration rate of the muscularis propria decreased in parafibromin-positive urinary system carcinomas. The parafibromin positivity rate was higher in carcinomas of the papillary type and in those of the lower urinary system. The question remains whether these features can be used as guiding parameters in tumor subgroups where the follow-up criteria have not been fully standardized, such as with papillary UCs. Parafibromin expression was lower in higher-grade tumors, although this difference from lower-grade tumors was not statistically significant. Parafibromin negativity might provide guidance on adjuvant therapy in cases with poor prognostic parameters such as urothelial carcinoma with squamous differentiation. All of these statements require support from studies based on larger groups with longer follow-up periods.
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![Parafibromin staining in differant types of urothelial carcinomas. (A) Parafibromin positivity on immunohistochemical evaluation of non-invasive high-grade papillary urothelial carcinoma. (B) Parafibromin positivity in the invasive areas of high-grade urothelial carcinoma of the bladder. (C) Partial parafibromin positivity in non-invasive low-grade papillary urothelial carcinoma. (D) Parafibromin negativity in non-invasive high-grade papillary urothelial carcinoma.](jptm-49-5-389f1){#f1-jptm-49-5-389}

![Parafibromin negativity in minimally invasive high-grade papillary urothelial carcinoma of the ureter. (A) Morphological features of urothelial carcinoma. (B) Parafibromin negativity in the same tumor.](jptm-49-5-389f2){#f2-jptm-49-5-389}

![Parafibromin negativity in invasive high-grade papillary urothelial carcinoma of the bladder. (A) Morphological features of urothelial carcinoma. (B) Parafibromin negativity in areas of muscularis propria invasion of the same tumor.](jptm-49-5-389f3){#f3-jptm-49-5-389}

![Parafibromin positivity in normal urothelial epithelium.](jptm-49-5-389f4){#f4-jptm-49-5-389}

###### 

Clinical and histopathological features of the patients

  Clinical and histopathological features                      No. of cases (%)
  ------------------------------------------------------------ ------------------
  Gender                                                       
   Male                                                        42 (85.7)
   Female                                                      7 (14.3)
  Tumor type                                                   
   Papillary UC                                                27 (55.1)
   Non-papillary UC                                            22 (44.9)
  Tumor grade                                                  
   Low                                                         7 (14.3)
   High                                                        42 (85.7)
  Muscularis propria invasion                                  
   Present                                                     21 (42.8)
   Absent                                                      28 (57.2)
  Latest health status                                         
   Alive                                                       46 (93.9)
   Dead                                                        3 (6.1)
  Recurrences                                                  
   Present                                                     20 (40.8)
    One                                                        14 (28.6)
    More                                                       6 (12.2)
   Absent                                                      29 (59.2)
  Progression^[a](#tfn1-jptm-49-5-389){ref-type="table-fn"}^   
   Absent                                                      30 (61.2)
   Present                                                     19 (38.8)

UC, urothelial carcinoma.

Progression is accepted when the tumor developed invasive features/deep invasion/lymph node metastasis/distant organ metastasis.

###### 

The relationship between tumor subtype and clinico-pathologic parameters

  Clinico-pathologic parameters   Papillary subtype (n=27)   Non-papillary subtype (n=22)   p-value
  ------------------------------- -------------------------- ------------------------------ ---------
  Gender                                                                                    .385
   Male                           3                          4                              
   Female                         24                         18                             
  Tumor grade                                                                               .01
   Low                            7                          0                              
   High                           20                         22                             
  Muscularis propria invasion                                                               .001
   Absent                         19                         2                              
   Present                        8                          20                             
  Tumor localization                                                                        .153
   Upper urinary system           7                          10                             
   Lower urinary system           20                         12                             
  Latest health status                                                                      .071
   Alive                          27                         19                             
   Dead                           0                          3                              
  Recurrences                                                                               .110
   Present                                                                                  
    One                           5                          9                              
    More                          5                          1                              
   Absent                         17                         12                             
  Progression                                                                               .683
   Absent                         17                         13                             
   Present                        10                         9                              

###### 

The relationship between parafibromin expression and clinicopathologic parameters

  Clinicopathologic parameter                                  Parafibromin expression   p-value        
  ------------------------------------------------------------ ------------------------- --------- ---- ------
  Gender                                                                                                .569
   Male                                                        10                        17        15   
   Female                                                      3                         2         2    
  Tumor type                                                                                            .111
   Papillary UC                                                6                         14        7    
   Non-papillary UC                                            7                         5         10   
  Tumor grade                                                                                           .105
   Low                                                         0                         5         2    
   High                                                        13                        14        15   
  Muscularis propria invasion                                                                           .007
   Absent                                                      1                         12        8    
   Present                                                     12                        7         9    
  Tumor localization                                                                                    .009
   Upper urinary system                                        9                         4         4    
   Lower urinary system                                        4                         15        13   
  Latest health status                                                                                  .353
   Alive                                                       13                        19        14   
   Dead                                                        0                         0         3    
  Disease-free survival                                        13                        19        17   .311
  Recurrences                                                                                           .573
   Present                                                                                              
    One                                                        2                         6         6    
    More                                                       1                         2         3    
   Absent                                                      10                        11        8    
  Progression^[a](#tfn2-jptm-49-5-389){ref-type="table-fn"}^                                            .183
   Absent                                                      10                        12        8    
   Present                                                     3                         7         9    

UC, urothelial carcinoma.

Progression is accepted when the tumor developed invasive features/deep invasion/lymph node metastasis/distant organ metastasis.
